Skip to main content

About Reshma Mahtani

Reshma Mahtani, D.O., is a medical oncologist at Miami Cancer Institute and chief of breast medical oncology for Baptist Health Wellness and Medical Complex. Dr. Mahtani’s practice is limited to the treatment of breast cancer. Prior to joining Miami Cancer Institute in 2022, Dr. Mahtani worked as an associate professor of medicine and co-leader of the Breast Cancer Site Disease Group at the University of Miami Miller School of Medicine. She was also the director of community outreach. Dr. Mahtani is an active clinical researcher, helping bring novel breast cancer treatments and clinical trials to patients in South Florida. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals. She is a nationally recognized thought leader in breast cancer and has presented her cancer research findings at cancer conferences worldwide. She has received funding from numerous organizations. Dr. Mahtani served on national committees to recognize cancer clinics that offer quality care across the country. She is involved in several initiatives that enhance patients’ access to healthcare, as well as community collaborations for education and advocacy. She founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Though she is a passionate researcher, Dr. Mahtani most enjoys spending time with her patients. She believes it is a privilege to be by their side, teaching them about their breast cancer and their treatment options. She strives to help every patient find hope through clinical trials and the latest immunotherapies and targeted therapies for breast cancer.

Positions

2022 - Present Chief of Breast Medical Oncology, Baptist Health South Florida ‐ Miami Cancer Institute
to
2019 - 2021 Breast Program Director, Deerfield Beach
to
2019 - 2021 Director of Community Outreach, University of Miami ‐ Sylvester Cancer Center
to
2010 - 2021 Associate Professor of Medicine / Co-Leader of Breast Cancer Site Disease Group, University of Miami ‐ Miller School of Medicine
to
2007 - 2017 Physician, Boca Raton Regional Hospital
to
2007 - 2010 Hematologist/Medical Oncologist / Director of Clinical Research, Boca Raton Regional Hospital ‐ Boca Raton Comprehensive Cancer Center
to
2007 - 2010 Physician, West Boca Hospital
to
2007 - 2010 Physician, Delray Hospital
to
1995 - 1997 Emergency Medical Technician, Rocky Hill Ambulance Association
to
1995 - 1997 Research Assistant, University of Connecticut ‐ Health Center
to
1994 - 1995 Research Assistant, Massachusetts General Hospital
to
1989 - 1994 Pharmaceutical Technician, Cromwell Pharmacy
to

Disciplines

Research Interests

Grants

2021 - 2022 Multimodal and temporal deep learning for designing optimal breast cancer treatment plans.
University of Miami, Sylvester Comprehensive Cancer Center
Sylvester CCSG Big Idea Award
Role: Co-investigator
Colleague(s): Principle Investigator: Mohamed Abdel-Mottaleb
2017 - 2021 Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer
Pfizer
Role: Principal Investigator
2016 - 2020 A Phase I/II Study to evaluate the safety and efficacy of vinorelbine with trastuzumab emtansine in pre-treated HER2-positive metastatic breast cancer
University of Miami, Sylvester Comprehensive Cancer Center
Role: Principal Investigator
2016 - 2020 Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)
Agendia
Role: Principal Investigator
2015 - 2019 A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, Her 2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting.
Lily
Role: Principal Investigator
2014 - 2019 NSABP B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
NSABP
Role: Principal Investigator
2015 - 2018 MONA-7: A Phase III Randomized, Double-blind, placebo-controlled study of MONA-7: LEE011 or Placebo in Combination with Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER 2-Negative, Advanced Breast Cancer
Novartis
Role: Principal Investigator
2014 - 2018 Multicenter, randomized, doubleblinded, placebo controlled, phase 3 trial of Fulvestrant (Faslodex) with or without PD0332991 (Palbociclib) Goserelin in women with hormone receptor positive, Her2 2 Negative metastatic breast cancer whose disease progressed after prior endocrine therapy
Pfizer
Role: Principal Investigator
2014 - 2017 A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer
Medivation
Role: Principal Investigator
2013 - 2017 BioMarin 301: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease
Biomarin, Medivation/Pfizer
Role: Principal Investigator
2013 - 2017 TRIO22/Paloma-2: A Randomized, Multicenter, Double-Blind Phase 3 Study of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease
Pfizer
Role: Principal Investigator
2010 - 2016 PARP Inhibition After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer on ER/PR, HER2 Negative with Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09146
Hoosier Oncology Group (HOG)
Role: Principal Investigator
2011 - 2015 A Phase III randomized, multicenter, two arm, open label trial to evaluate the efficacy of TDM1 compared with treatment of physician’s choice in patients with HER 2 positive metastatic breast cancer who have received at least two prior regimens of HER2 directed therapy
Genentech/Roche
Role: Principal Investigator
2011 - 2015 Mavericc: A randomized phase II study of Bevacizumab/mFolfox6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer
Genentech/Roche
Role: Principal Investigator
$
to
Enter a valid date range.

Professional Service and Affiliations

2020 - Present Member, American Cancer Society, ResearcHERS Medical Advisory Board
2019 - Present Member, Living Beyond Breast Cancer Medical Advisory Board
2017 - Present Member, Florida Society of Clinical Oncology (FLASCO) Board of Directors
2016 - Present Breast Cancer Editorial Board, Practice Updates (Elsevier Science)
2007 - Present American Board of Internal Medicine, Member
2004 - Present Member, American Society of Clinical Oncology
Present Ad Hoc Journal Reviewer, Journal of Clinical Oncology, Lung Cancer, Future Oncology
2018 - 2021 Institutional Representative University of Miami, CARE Consortium
2018 - 2021 Institutional Representative University of Miami, National Surgical Adjuvant Breast and Bowel Project (NSABP)
2016 - 2021 Editorial Board Member, The Breast Journal
2014 - 2021 Member, University of Miami Data Safety Monitoring Committee
2016 - 2019 Steering Committee Member, ASCO Quality Oncology Practice Initiative (QOPI)
2014 - 2019 Member, University of Miami Clinical Trials Acceleration Grant Review Committee
2016 - 2018 Member, Breast Committee Group, Eastern Cooperative Oncology Group (ECOG)
2016 - 2017 Member, American Cancer Society, Physician Board
2015 - 2016 Peer reviewer, PRIME Monographs
2014 - 2015 Committee Chief, University of Miami GYN Cytology Search Committee
2008 - 2010 Speaker, FORCE. Facing Our Risk of Cancer Empowered. Organization
2008 - 2010 Speaker, Gilda's Club. Cancer Emotional and Social support organization
2009 - 2009 Associate Guest Editor, Clinical Therapeutics
to
Enter a valid date range.

Honors and Awards

  • Sigma Phi Honor Society, 1997
  • Graduated with High Honor (Mount Holyoke College), 1994
  • Howard Hughes Research Fellowship, 1994 – 1995

Education

to
2004 - 2007 Fellow, St.Vincents Catholic Medical Center
to
2002 - 2004 Resident, St.Vincents Catholic Medical Center
to
2001 - 2002 Internship, Yale University ‐ Greenwich Hospital
to
June 2001 Doctor, Osteopathic Medicine, University of New England
to
June 1997 Master of Science, Neuroscience, University of Connecticut
to
May 1994 Bachelor of Arts, Neuroscience, Mount Holyoke College
to

Links

Contact Information

Miami Cancer Institute
1228 South Pine Island Road, Suite 410
Plantation, FL 33324

Find a Doctor Profile / Dr. Reshma Mahtani

ORCID

Posters (14)

Presentations (2)